Search results for " transplantation"

showing 10 items of 1513 documents

Envelope approach for onlay bone grafting : preliminary surgical and prosthetic results

2009

Minimally invasive surgery principles have been applied to preprosthetic-implant surgery, and an adequate presurgical planning reduces morbidity in both harvesting and stabilization of the bone grafts. Objective: A new ?envelope? approach for onlay bone grafting at the alveolar process is presented, this avoids releasing incisions yet allowing adequate reconstruction of the defective site. Study design: To be included in the study the patient had to have an antero-posterior defect of the alveolar crest. Patient age and sex, location of the defect, type and size of graft, and complications appeared during follow up were recorded. Results: Ten consecutive patients (4 men and 6 women) have bee…

AdultMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentDentistryBone graftingYoung AdultMandibular bodyPatient ageAlveolar ProcessmedicineHumansIn patientProspective StudiesGeneral DentistryDental ImplantsBone Transplantationbusiness.industryAlveolar processMandibleMiddle Aged:CIENCIAS MÉDICAS [UNESCO]Mucoperiosteal FlapChinSurgeryTreatment Outcomemedicine.anatomical_structureOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASFemaleSurgerybusiness
researchProduct

Long-term outcome of ‘long-term liver transplant survivors’

2013

There are few studies focusing on long-term complications in liver transplant (LT) recipients. The aim of this study was to define the outcome of LT recipients having survived at least 10 years from LT. Of 323 adult LT done between 1991 and 1997, the 167(52%) alive >10 years post-LT (baseline time) formed the study population. Long-term outcome measures included the following: immunosuppression, metabolic complications [obesity, arterial hypertension (AH), diabetes, dislypidemia], cardiovascular events (CVE), chronic renal dysfunction-CRD, and de novo tumors. Median age at LT was 50 years. Most common indication was postnecrotic cirrhosis (89%), mostly because of HCV (46%). At study-baselin…

AdultMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentLiver transplantationPostnecrotic cirrhosisRisk FactorsCause of DeathInternal medicineDiabetes mellitusmedicineHumansSurvivorsAgedRetrospective StudiesCause of deathTransplantationbusiness.industryImmunosuppressionRetrospective cohort studyMiddle Agedmedicine.diseaseObesityLiver TransplantationSurgeryTreatment OutcomePopulation studyFemalebusinessTransplant International
researchProduct

Liver transplanted patients with preoperative autoimmune hepatitis and immunological disorders are at increased risk for Post-Transplant Lymphoprolif…

2010

Long term immunosuppression and therapy of acute rejections result in a 20-120-fold increased risk to develop Non Hodgkin lymphoma (NHL). Since immunosuppressive therapy and immunological disorders are major risk factors for the development of NHL in the non-transplant population we aimed to analyze risk factors for PTLD in our cohort of liver transplanted (LT) patients.We analyzed retrospectively 431 patients liver transplanted between 1998 and 2008.PTLD was diagnosed in eleven of 431 patients (2.6%). PTLD, especially late PTLD, was significantly more frequent in patients who received steroids before LT (Kaplan-Meier: p0.001). Moreover PTLD in immunocompromised patients with preoperative s…

AdultMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentPopulationAutoimmune hepatitisKaplan-Meier EstimateLiver transplantationGastroenterologyYoung AdultPostoperative ComplicationsRisk Factorshemic and lymphatic diseasesInternal medicinePreoperative CareInternal MedicinemedicineCadaverHumansProspective cohort studyeducationChildAgedProportional Hazards ModelsRetrospective StudiesHepatitiseducation.field_of_studybusiness.industryLymphoma Non-HodgkinRetrospective cohort studyImmunosuppressionMiddle Agedmedicine.diseaseTissue DonorsLymphomaLiver TransplantationHepatitis Autoimmunesurgical procedures operativeImmunologyMultivariate AnalysisFemaleSteroidsbusinessImmunosuppressive AgentsEuropean journal of internal medicine
researchProduct

Spontaneously‐resolving episodes of cytomegalovirus DNAemia in allogeneic hematopoietic stem cell transplant recipients: Virological features and cli…

2018

It has been reported that low-plasma cytomegalovirus (CMV) DNA loads are associated with an increased risk of overall mortality in allogeneic hematopoietic stem cell transplantation (allo-HSCT). Utilizing a conservative strategy for initiation of preemptive antiviral therapy (>1500 IU/mL), we characterized the virological features of spontaneously-resolving episodes of CMV DNAemia and assessed their impact on mortality through the first year after transplantation. We reviewed the CMV DNA polymerase chain reaction results and clinical charts of 230 consecutive adult patients who underwent T-cell replete allo-HSCT at our center. A total of 280 episodes of CMV DNAemia were registered in 164 pa…

AdultMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentRemission SpontaneousCongenital cytomegalovirus infectionCytomegalovirusHematopoietic stem cell transplantationGastroenterologyYoung Adult03 medical and health sciences0302 clinical medicineVirologyInternal medicinemedicineHumansTransplantation HomologousIn patient030212 general & internal medicineAgedRetrospective Studiesbusiness.industryHematopoietic Stem Cell Transplantationvirus diseasesCmv dnaemiaMiddle AgedViral Loadmedicine.diseaseVirologyTransplant RecipientsConservative strategyTransplantationInfectious DiseasesIncreased riskCytomegalovirus InfectionsDNA ViralFemale030211 gastroenterology & hepatologyAllogeneic hematopoietic stem cell transplantbusinessJournal of Medical Virology
researchProduct

Autogenous tooth transplantation : evaluation of pulp tissue regeneration

2010

Objective: The aim of this study was to assess the pulp survival that occur in transplants of autologous teeth, by comparing two surgical techniques: the conventional technique (autotransplantation for newly formed alveoli), and an alternative technique, (autotransplants for alveoli in the initial phase of healing). In each surgical techniques were applied, randomly, either saline solution or Emdogain ®. Study Design:The study group comprised 26 patents, in which 28 teeth were transplanted to recipient sockets prepared mechanically. Of the 28 teeth transplanted, 4 were intentional replants, and of the remainer, 11 had the apex closed and 13 open. The mean age at the time of transplantation …

AdultMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentRoot canalImplante DentárioDentistryRegeneração ÓsseaPolpa DentáriaTransplantation AutologousYoung AdultDental Enamel ProteinsmedicineHumansRegenerationChildGeneral DentistrySalineDental PulpConventional techniquePeriodontitisTransplantação de Ossobusiness.industryTooth transplantationmedicine.disease:CIENCIAS MÉDICAS [UNESCO]AutotransplantationSurgeryTransplantationstomatognathic diseasesmedicine.anatomical_structureOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASPulp (tooth)FemaleSurgerybusinessTooth
researchProduct

Filgrastim mobilization and collection of allogeneic blood progenitor cells from adult family donors: first interim report of a prospective German mu…

2002

Recombinant human granulocyte colony-stimulating factor (rhG-CSF) mobilized peripheral blood progenitor cells (PBPCs) from healthy individuals are a rapidly emerging alternative source to bone marrow for allogeneic transplantation. Although widely applied in the meantime, only limited information on feasibility and safety of mobilization and collection of PBPCs is currently available from prospective multicenter studies specifically designed to investigate this donation modality. This ongoing multicenter study on the performance as well as the short- and long-term safety profile of rhG-CSF-induced mobilization and collection of PBPCs was initiated in October 1999. The study is designed to r…

AdultMalemedicine.medical_specialtyAllogeneic transplantationAdolescentFilgrastimAntigens CD34Blood DonorsFilgrastimImmunophenotypingNuclear FamilyInternal medicineGranulocyte Colony-Stimulating FactormedicineClinical endpointHumansLeukapheresisProspective StudiesProspective cohort studyAdverse effectbusiness.industryHematologyGeneral MedicineLeukapheresisMiddle AgedHematopoietic Stem Cell MobilizationLymphocyte SubsetsRecombinant ProteinsGranulocyte colony-stimulating factorSurgeryBlood Cell CountRegimenImmune SystemFemalebusinessmedicine.drugAnnals of hematology
researchProduct

Total body irradiation and cyclophosphamide is a conditioning regimen for unrelated bone marrow transplantation in a patient with chronic myelogenous…

1998

Five years after the diagnosis of Ph chromosome-positive chronic myeloid leukemia (CML) a 31-year-old patient developed malignant nephrosclerosis with renal failure. He then underwent an allogeneic unrelated BMT in first chronic phase CML. The preparative regimen consisted of fractionated total body irradiation (TBI) and cyclophosphamide (CY). We studied the pharmacokinetics of cyclophosphamide on hemodialysis and compared clinical parameters including time to engraftment and toxicity with parameters of a patient with normal renal function who also received an unrelated marrow as treatment for CML in first chronic phase. Our results suggest that TBI/CY is a suitable conditioning regimen for…

AdultMalemedicine.medical_specialtyAllogeneic transplantationTransplantation ConditioningCyclophosphamidemedicine.medical_treatmentGastroenterologyRenal Dialysishemic and lymphatic diseasesInternal medicineLeukemia Myelogenous Chronic BCR-ABL PositivemedicineHumansTransplantation HomologousAntineoplastic Agents AlkylatingCyclophosphamidePreparative RegimenBone Marrow TransplantationTransplantationChemotherapyNephrosclerosisbusiness.industryHematologyTotal body irradiationmedicine.diseaseSurgeryCase-Control StudiesKidney Failure ChronicHemodialysisbusinessWhole-Body Irradiationmedicine.drugKidney diseaseChronic myelogenous leukemiaBone marrow transplantation
researchProduct

Chemotherapy-induced mobilization of karyotypically normal PBSC for autografting in CML

1998

High-dose chemotherapy with autologous transplantation of in vivo purged PBSC is a new and interesting therapeutic option for CML patients not eligible for allogeneic transplantation. We investigated the feasibility and toxicity of this approach in 57 patients with Ph-positive CML. For mobilization of Ph-negative PBSC, patients were treated either with '5 + 2/7 + 3'- type chemotherapy or with 'mini-ICE/ICE' chemotherapy followed by administration of G-CSF. Fourteen patients were in early chronic phase, 30 patients in late chronic phase and 13 patients in accelerated phase (AP) or blast crisis (BC). Cytogenetic responses in the PBSC harvests were dependent on both disease stage and type of c…

AdultMalemedicine.medical_specialtyAllogeneic transplantationmedicine.medical_treatmentPilot ProjectsLeukemia Myelogenous Chronic BCR-ABL PositiveAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAutologous transplantationProspective StudiesEtoposideTransplantationMyelosuppressive ChemotherapyChemotherapybusiness.industryHematopoietic Stem Cell TransplantationHematologyMiddle AgedHematopoietic Stem Cell MobilizationGranulocyte colony-stimulating factorSurgeryTransplantationKaryotypingCytarabineFemalebusinessmedicine.drugBone Marrow Transplantation
researchProduct

Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem‐cell transplantation

2011

Antifungal prophylaxis for allogeneic haematopoietic stem-cell transplant (alloHCT) recipients should prevent invasive mould and yeast infections (IFIs) and be well tolerated. This prospective, randomized, open-label, multicentre study compared the efficacy and safety of voriconazole (234 patients) versus itraconazole (255 patients) in alloHCT recipients. The primary composite endpoint, success of prophylaxis, incorporated ability to tolerate study drug for ≥100 d (with ≤14 d interruption) with survival to day 180 without proven/probable IFI. Success of prophylaxis was significantly higher with voriconazole than itraconazole (48·7% vs. 33·2%, P 10%) treatment-related adverse events were vom…

AdultMalemedicine.medical_specialtyAntifungal AgentsAdolescentItraconazoleazolesstem-cell transplantPharmacologyBiologyAspergillosisGastroenterologyYoung AdultInternal medicineAmphotericin BmedicineHumansTransplantation Homologousyeast infectionsProspective StudiesChildAdverse effectAgedVoriconazoleHaematological MalignancyHematopoietic Stem Cell TransplantationHematologyMiddle AgedTriazolesmedicine.diseaseinvasive fungal diseaseTransplantationPyrimidinesMycosesmould infectionsFemaleVoriconazoleLiver functionItraconazoleFluconazolemedicine.drugBritish Journal of Haematology
researchProduct

Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Res…

2010

Caspofungin at standard dose was evaluated as first-line monotherapy of mycologically documented probable/proven invasive aspergillosis (IA) (unmodified European Organisation for Research and Treatment of Cancer/Mycosis Study Group criteria) in allogeneic hematopoietic SCT patients. The primary efficacy end point was complete or partial response at end of caspofungin treatment. Response at week 12, survival and safety were additional end points. Enrollment was stopped prematurely because of low accrual, with 42 enrolled and 24 eligible, giving the study a power of 85%. Transplant was from unrelated donors in 16 patients; acute or chronic GVHD was present in 15. In all, 12 patients were neut…

AdultMalemedicine.medical_specialtyAntifungal AgentsDrug-Related Side Effects and Adverse Reactionsmedicine.medical_treatmentGraft vs Host DiseaseHematopoietic stem cell transplantationAspergillosischemistry.chemical_compoundEchinocandinsLipopeptidesYoung AdultPharmacotherapyCaspofunginInternal medicineMedicineAspergillosisHumansTransplantation HomologousaspergillosiscaspofunginAdverse effectSurvival rateAgedallogeneicTransplantationbusiness.industryHematopoietic Stem Cell Transplantationhematopoietic SCTHematologyMiddle Agedmedicine.diseaseSurgeryCalcineurinTransplantationEuropeSurvival RateTreatment OutcomechemistryDrug Therapy CombinationFemaleCaspofunginbusinessBone marrow transplantation
researchProduct